Identification of novel synergistic targets for rational drug combinations with PI3 kinase inhibitors using siRNA synthetic lethality screening against GBM

Cellular and in vivo activity of a novel PI3K inhibitor, PX-866, against human glioblastoma

(2010) D. Koul et al.   NEURO-ONCOLOGY

Unsupervised Analysis of Transcriptomic Profiles Reveals Six Glioma Subtypes

(2009) A. Li et al.   CANCER RESEARCH

NVP-BEZ235, a novel dual phosphatidylinositol 3-kinase/mammalian target of rapamycin inhibitor, elicits multifaceted antitumor activities in human gliomas

(2009) T.-J. Liu et al.   MOLECULAR CANCER THERAPEUTICS

Synthetic Lethality — A New Direction in Cancer-Drug Development

(2009) J. Dirk Iglehart et al.   NEW ENGLAND JOURNAL OF MEDICINE

High-Resolution Melting Analysis for Rapid Detection ofKRAS, BRAF,andPIK3CAGene Mutations in Colorectal Cancer

(2008) Lisa Simi et al.   AMERICAN JOURNAL OF CLINICAL PATHOLOGY

NVP-BEZ235, a Dual PI3K/mTOR Inhibitor, Prevents PI3K Signaling and Inhibits the Growth of Cancer Cells with Activating PI3K Mutations

(2008) V. Serra et al.   CANCER RESEARCH

Phosphatidylinositol 3-Kinase Inhibition Broadly Sensitizes Glioblastoma Cells to Death Receptor- and Drug-Induced Apoptosis

(2008) D. Opel et al.   CANCER RESEARCH

Mechanisms of Acquired Resistance to Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitors in Non-Small Cell Lung Cancer

(2008) J. A. Engelman et al.   CLINICAL CANCER RESEARCH

PTEN deficiency causes dyschondroplasia in mice by enhanced hypoxia-inducible factor 1  signaling and endoplasmic reticulum stress

(2008) G. Yang et al.   DEVELOPMENT

mTOR inhibitors in the treatment of cancer

(2008) Angelica Fasolo et al.   EXPERT OPINION ON INVESTIGATIONAL DRUGS

Comprehensive genomic characterization defines human glioblastoma genes and core pathways

(2008) Roger McLendon et al.   NATURE

Effective use of PI3K and MEK inhibitors to treat mutant Kras G12D and PIK3CA H1047R murine lung cancers

(2008) Jeffrey A Engelman et al.   NATURE MEDICINE

Neurooncology clinical trial design for targeted therapies: Lessons learned from the North American Brain Tumor Consortium

(2008) Susan M. Chang et al.   NEURO-ONCOLOGY

Breast Tumor Cells with PI3K Mutation or HER2 Amplification Are Selectively Addicted to Akt Signaling

(2008) Qing-Bai She et al.   PLoS One